Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Since traditional drug research and development is often time-consuming and high-risk, there is an increasing interest in establishing new medical indications for approved drugs, referred to as drug repositioning, which provides a relatively low-cost and high-efficiency approach for drug discovery. With the explosive growth of large-scale biochemical and phenotypic data, drug repositioning holds great potential for precision medicine in the post-genomic era. It is urgent to develop rational and systematic approaches to predict new indications for approved drugs on a large scale. RESULTS: In this paper, we propose the two-pass random walks with restart on a heterogenous network, TP-NRWRH for short, to predict new indications for approved drugs. Rather than random walk on bipartite network, we integrated the drug-drug similarity network, disease-disease similarity network and known drug-disease association network into one heterogenous network, on which the two-pass random walks with restart is implemented. We have conducted performance evaluation on two datasets of drug-disease associations, and the results show that our method has higher performance than six existing methods. A case study on the Alzheimer's disease showed that nine of top 10 predicted drugs have been approved or investigational for neurodegenerative diseases. The experimental results show that our method achieves state-of-the-art performance in predicting new indications for approved drugs. CONCLUSIONS: We proposed a two-pass random walk with restart on the drug-disease heterogeneous network, referred to as TP-NRWRH, to predict new indications for approved drugs. Performance evaluation on two independent datasets showed that TP-NRWRH achieved higher performance than six existing methods on 10-fold cross validations. The case study on the Alzheimer's disease showed that nine of top 10 predicted drugs have been approved or are investigational for neurodegenerative diseases. The results show that our method achieves state-of-the-art performance in predicting new indications for approved drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
The common biology of cancer and ageing
Finkel, T., Serrano, M., & Blasco, M. A. (2007) · Nature · doi:10.1038/nature05985 · Cited by 988
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders
Hamosh, A. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.52 · Cited by 762
Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons
Guo, J. L., Covell, D. J., Daniels, J. P., Iba, M., Stieber, A., Zhang, B., Riddle, D. M., Kwong, L. K., Xu, Y., Trojanowski, J. Q., et al. (2013) · Cell · doi:10.1016/j.cell.2013.05.057 · Cited by 680
Drug repositioning: a machine-learning approach through data integration
Napolitano, F., Zhao, Y., Moreira, V. M., Tagliaferri, R., Kere, J., D’Amato, M., & Greco, D. (2013) · Journal of Cheminformatics · doi:10.1186/1758-2946-5-30 · Cited by 349 · cited 1×
“Most machine learning-based methods take randomly generated drug-disease associations as negative samples, in which some false negatives are included and lead to biased decision boundary [7, 11].”
Background
Cited by
Artificial intelligence in cancer target identification and drug discovery
You, Y., Lai, X., Pan, Y., Zheng, H., Vera, J., Liu, S., Deng, S., & Zhang, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00994-0 · Cited by 435
Constructing knowledge graphs and their biomedical applications
Nicholson, D. N., & Greene, C. S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.05.017 · Cited by 299
Peng, J., Li, J., & Shang, X. (2020) · BMC Bioinformatics · doi:10.1186/s12859-020-03677-1 · Cited by 133
“…matrix B according to the A i , j , whose elements B i , j describe the transition probability from the drug node i to the disease node j [23], that is defined as follows: Next, the final drug-disease diffusion state matrix can be obtained by iterative convergence as follows: Where S ti…”
BackgroundPathway-Guided Deep Neural Network toward Interpretable and Predictive Modeling of Drug Sensitivity
Deng, L., Cai, Y., Zhang, W., Yang, W., Gao, B., & Liu, H. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00331 · Cited by 71
Self-citationDrug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257700 · Cited by 55
“…included studies developing general drug repurposing tools and making predictions for AD (Wu et al., 2013; Croset et al., 2014; Issa et al., 2016; Liu et al., 2016; Jiang et al., 2019; Yu and Gao, 2019; Zeng et al., 2019; Cai et al., 2021; Chen et al., 2021; Tsuji et al., 2021; Muslu et al.,…”
Background
Metadata
- Authors
- Liu, H., Song, Y., Guan, J., Luo, L., & Zhuang, Z.
- Venue
- BMC Bioinformatics
- Published
- 2016-12
- Volume
- 17
- Issue
- S17
- Pages
- 539-539
- ISSN
- 1471-2105 (ISSN-L)
- OpenAlex
- W2562110925
- Cited by
- 92
- References
- 6
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks. https://app.cochat.ai/papers/10.1186/s12859-016-1336-7
- The paper
- Liu, H., Song, Y., Guan, J., Luo, L., & Zhuang, Z. (2016). Inferring new indications for approved drugs via random walk on drug-disease heterogenous networks. BMC Bioinformatics. https://doi.org/10.1186/s12859-016-1336-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.